Adjuvant Holdings reports Q2 revenue and profit decline

For the second quarter of the fiscal year ending March 2026, Adjuvant Holdings reported consolidated net sales of JPY 1,855 million, a 10.8% decrease compared to the previous year. Operating loss for the period was JPY 21 million, contrasting with an operating profit of JPY 55 million in the prior year. Ordinary loss also reached JPY 15 million, down from JPY 55 million in ordinary profit last year.

Net income attributable to owners of the parent company fell to JPY 15 million, marking a 12.4% decrease. Diluted earnings per share for the interim period were JPY 1.99, a decline from JPY 2.28 in the same period last year. Total comprehensive income for the quarter was JPY 10 million, a 57.8% decrease from JPY 25 million in the prior year.

The company's full-year forecast for the fiscal year ending March 2026 remains unchanged, projecting net sales of JPY 4,365 million and net income attributable to owners of the parent of JPY 73 million, resulting in JPY 9.22 per share. The dividend forecast for the second quarter is JPY 0.00, with a year-end forecast of JPY 12.00, making a total annual dividend of JPY 12.00.